Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
China-Singapore Guangzhou Knowledge City (CSGKC) is a premier state-level bilateral project between China and Singapore, managed by a joint venture between CapitaLand and the Guangzhou Development District. It serves as a strategic hub for high-tech industries, with a core focus on the biopharmaceutical, healthcare, and next-generation ICT sectors. The city features a dedicated Biopharmaceutical Park that provides world-class infrastructure, including GMP-compliant manufacturing facilities and R&D centers, to support the entire life sciences value chain. CSGKC has successfully attracted global leaders and high-growth biotech firms such as BeiGene, Akeso, and InnoCare, positioning itself as a central node in the Guangdong-Hong Kong-Macao Greater Bay Area's innovation ecosystem. The entity facilitates cross-border collaborations and provides comprehensive services to accelerate the commercialization of innovative therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China-Singapore Guangzhou Knowledge City.